Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities

There are no FDA-approved drugs to mitigate the delayed effects of radiation exposure that may occur after a radiological attack or nuclear accident. To date, angiotensin-converting enzyme inhibitors are one of the most successful candidates for mitigation of hematopoietic, lung, kidney, and brain i...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Pharmacol
Autores principales: Medhora, Meetha, Phadnis, Preeya, Narayanan, Jayashree, Gasperetti, Tracy, Zielonka, Jacek, Moulder, John E., Fish, Brian L., Szabo, Aniko
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8111401/
https://ncbi.nlm.nih.gov/pubmed/33986677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.646076
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares